Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive
The sequential algorithm for fibrosis evaluation (SAFE) and the Bordeaux algorithm (BA), which cross‐check FibroTest with the aspartate aminotransferase‐to‐platelet ratio index (APRI) or FibroScan, are very accurate but provide only a binary diagnosis of significant fibrosis (SAFE or BA for Metavir...
Saved in:
| Published in | Hepatology (Baltimore, Md.) Vol. 55; no. 1; pp. 58 - 67 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
01.01.2012
Wiley Wolters Kluwer Health, Inc Wiley-Blackwell |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0270-9139 1527-3350 1527-3350 |
| DOI | 10.1002/hep.24654 |
Cover
| Abstract | The sequential algorithm for fibrosis evaluation (SAFE) and the Bordeaux algorithm (BA), which cross‐check FibroTest with the aspartate aminotransferase‐to‐platelet ratio index (APRI) or FibroScan, are very accurate but provide only a binary diagnosis of significant fibrosis (SAFE or BA for Metavir F ≥ 2) or cirrhosis (SAFE or BA for F4). Therefore, in clinical practice, physicians have to apply the algorithm for F ≥ 2, and then, when needed, the algorithm for F4 (“successive algorithms”). We aimed to evaluate successive SAFE, successive BA, and a new, noninvasive, detailed classification of fibrosis. The study included 1785 patients with chronic hepatitis C, liver biopsy, blood fibrosis tests, and FibroScan (the latter in 729 patients). The most accurate synchronous combination of FibroScan with a blood test (FibroMeter) provided a new detailed (six classes) classification (FM+FS). Successive SAFE had a significantly (P < 10−3) lower diagnostic accuracy (87.3%) than individual SAFE for F ≥ 2 (94.6%) or SAFE for F4 (89.5%), and required significantly more biopsies (70.8% versus 64.0% or 6.4%, respectively, P < 10−3). Similarly, successive BA had significantly (P ≤ 10−3) lower diagnostic accuracy (84.7%) than individual BA for F ≥ 2 (88.3%) or BA for F4 (94.2%), and required significantly more biopsies (49.8% versus 34.6% or 24.6%, respectively, P < 10−3). The diagnostic accuracy of the FM+FS classification (86.7%) was not significantly different from those of successive SAFE or BA. However, this new classification required no biopsy. Conclusion: SAFE and BA for significant fibrosis or cirrhosis are very accurate. However, their successive use induces a significant decrease in diagnostic accuracy and a significant increase in required liver biopsy. A new fibrosis classification that synchronously combines two fibrosis tests was as accurate as successive SAFE or BA, while providing an entirely noninvasive (0% liver biopsy) and more precise (six versus two or three fibrosis classes) fibrosis diagnosis. (HEPATOLOGY 2012;55:58–67) |
|---|---|
| AbstractList | The sequential algorithm for fibrosis evaluation (SAFE) and the Bordeaux algorithm (BA), which cross-check FibroTest with the aspartate aminotransferase-to-platelet ratio index (APRI) or FibroScan, are very accurate but provide only a binary diagnosis of significant fibrosis (SAFE or BA for Metavir F greater than or equal to 2) or cirrhosis (SAFE or BA for F4). Therefore, in clinical practice, physicians have to apply the algorithm for F greater than or equal to 2, and then, when needed, the algorithm for F4 ("successive algorithms"). We aimed to evaluate successive SAFE, successive BA, and a new, noninvasive, detailed classification of fibrosis. The study included 1785 patients with chronic hepatitis C, liver biopsy, blood fibrosis tests, and FibroScan (the latter in 729 patients). The most accurate synchronous combination of FibroScan with a blood test (FibroMeter) provided a new detailed (six classes) classification (FM+FS). Successive SAFE had a significantly (P < 10 super(-3)) lower diagnostic accuracy (87.3%) than individual SAFE for F greater than or equal to 2 (94.6%) or SAFE for F4 (89.5%), and required significantly more biopsies (70.8% versus 64.0% or 6.4%, respectively, P < 10 super(-3)). Similarly, successive BA had significantly (P less than or equal to 10 super(-3)) lower diagnostic accuracy (84.7%) than individual BA for F greater than or equal to 2 (88.3%) or BA for F4 (94.2%), and required significantly more biopsies (49.8% versus 34.6% or 24.6%, respectively, P < 10 super(-3)). The diagnostic accuracy of the FM+FS classification (86.7%) was not significantly different from those of successive SAFE or BA. However, this new classification required no biopsy. Conclusion: SAFE and BA for significant fibrosis or cirrhosis are very accurate. However, their successive use induces a significant decrease in diagnostic accuracy and a significant increase in required liver biopsy. A new fibrosis classification that synchronously combines two fibrosis tests was as accurate as successive SAFE or BA, while providing an entirely noninvasive (0% liver biopsy) and more precise (six versus two or three fibrosis classes) fibrosis diagnosis. (HEPATOLOGY 2012; 55:58-67) The sequential algorithm for fibrosis evaluation (SAFE) and the Bordeaux algorithm (BA), which cross-check FibroTest with the aspartate aminotransferase-to-platelet ratio index (APRI) or FibroScan, are very accurate but provide only a binary diagnosis of significant fibrosis (SAFE or BA for Metavir F ≥ 2) or cirrhosis (SAFE or BA for F4). Therefore, in clinical practice, physicians have to apply the algorithm for F ≥ 2, and then, when needed, the algorithm for F4 ("successive algorithms"). We aimed to evaluate successive SAFE, successive BA, and a new, noninvasive, detailed classification of fibrosis. The study included 1785 patients with chronic hepatitis C, liver biopsy, blood fibrosis tests, and FibroScan (the latter in 729 patients). The most accurate synchronous combination of FibroScan with a blood test (FibroMeter) provided a new detailed (six classes) classification (FM+FS). Successive SAFE had a significantly (P < 10(-3) ) lower diagnostic accuracy (87.3%) than individual SAFE for F ≥ 2 (94.6%) or SAFE for F4 (89.5%), and required significantly more biopsies (70.8% versus 64.0% or 6.4%, respectively, P < 10(-3) ). Similarly, successive BA had significantly (P ≤ 10(-3) ) lower diagnostic accuracy (84.7%) than individual BA for F ≥ 2 (88.3%) or BA for F4 (94.2%), and required significantly more biopsies (49.8% versus 34.6% or 24.6%, respectively, P < 10(-3) ). The diagnostic accuracy of the FM+FS classification (86.7%) was not significantly different from those of successive SAFE or BA. However, this new classification required no biopsy.UNLABELLEDThe sequential algorithm for fibrosis evaluation (SAFE) and the Bordeaux algorithm (BA), which cross-check FibroTest with the aspartate aminotransferase-to-platelet ratio index (APRI) or FibroScan, are very accurate but provide only a binary diagnosis of significant fibrosis (SAFE or BA for Metavir F ≥ 2) or cirrhosis (SAFE or BA for F4). Therefore, in clinical practice, physicians have to apply the algorithm for F ≥ 2, and then, when needed, the algorithm for F4 ("successive algorithms"). We aimed to evaluate successive SAFE, successive BA, and a new, noninvasive, detailed classification of fibrosis. The study included 1785 patients with chronic hepatitis C, liver biopsy, blood fibrosis tests, and FibroScan (the latter in 729 patients). The most accurate synchronous combination of FibroScan with a blood test (FibroMeter) provided a new detailed (six classes) classification (FM+FS). Successive SAFE had a significantly (P < 10(-3) ) lower diagnostic accuracy (87.3%) than individual SAFE for F ≥ 2 (94.6%) or SAFE for F4 (89.5%), and required significantly more biopsies (70.8% versus 64.0% or 6.4%, respectively, P < 10(-3) ). Similarly, successive BA had significantly (P ≤ 10(-3) ) lower diagnostic accuracy (84.7%) than individual BA for F ≥ 2 (88.3%) or BA for F4 (94.2%), and required significantly more biopsies (49.8% versus 34.6% or 24.6%, respectively, P < 10(-3) ). The diagnostic accuracy of the FM+FS classification (86.7%) was not significantly different from those of successive SAFE or BA. However, this new classification required no biopsy.SAFE and BA for significant fibrosis or cirrhosis are very accurate. However, their successive use induces a significant decrease in diagnostic accuracy and a significant increase in required liver biopsy. A new fibrosis classification that synchronously combines two fibrosis tests was as accurate as successive SAFE or BA, while providing an entirely noninvasive (0% liver biopsy) and more precise (six versus two or three fibrosis classes) fibrosis diagnosis.CONCLUSIONSAFE and BA for significant fibrosis or cirrhosis are very accurate. However, their successive use induces a significant decrease in diagnostic accuracy and a significant increase in required liver biopsy. A new fibrosis classification that synchronously combines two fibrosis tests was as accurate as successive SAFE or BA, while providing an entirely noninvasive (0% liver biopsy) and more precise (six versus two or three fibrosis classes) fibrosis diagnosis. The sequential algorithm for fibrosis evaluation (SAFE) and the Bordeaux algorithm (BA), which cross-check FibroTest with the aspartate aminotransferase-to-platelet ratio index (APRI) or FibroScan, are very accurate but provide only a binary diagnosis of significant fibrosis (SAFE or BA for Metavir F ≥ 2) or cirrhosis (SAFE or BA for F4). Therefore, in clinical practice, physicians have to apply the algorithm for F ≥ 2, and then, when needed, the algorithm for F4 ("successive algorithms"). We aimed to evaluate successive SAFE, successive BA, and a new, noninvasive, detailed classification of fibrosis. The study included 1785 patients with chronic hepatitis C, liver biopsy, blood fibrosis tests, and FibroScan (the latter in 729 patients). The most accurate synchronous combination of FibroScan with a blood test (FibroMeter) provided a new detailed (six classes) classification (FM+FS). Successive SAFE had a significantly (P < 10-3) lower diagnostic accuracy (87.3%) than individual SAFE for F ≥ 2 (94.6%) or SAFE for F4 (89.5%), and required significantly more biopsies (70.8% versus 64.0% or 6.4%, respectively, P < 10-3). Similarly, successive BA had significantly (P ≤ 10-3) lower diagnostic accuracy (84.7%) than individual BA for F ≥ 2 (88.3%) or BA for F4 (94.2%), and required significantly more biopsies (49.8% versus 34.6% or 24.6%, respectively, P < 10-3). The diagnostic accuracy of the FM+FS classification (86.7%) was not significantly different from those of successive SAFE or BA. However, this new classification required no biopsy. Conclusion: SAFE and BA for significant fibrosis or cirrhosis are very accurate. However, their successive use induces a significant decrease in diagnostic accuracy and a significant increase in required liver biopsy. A new fibrosis classification that synchronously combines two fibrosis tests was as accurate as successive SAFE or BA, while providing an entirely noninvasive (0% liver biopsy) and more precise (six versus two or three fibrosis classes) fibrosis diagnosis. (HEPATOLOGY 2012;55:58-67) UNLABELLED: The sequential algorithm for fibrosis evaluation (SAFE) and the Bordeaux algorithm (BA), which cross-check FibroTest with the aspartate aminotransferase-to-platelet ratio index (APRI) or FibroScan, are very accurate but provide only a binary diagnosis of significant fibrosis (SAFE or BA for Metavir F ≥ 2) or cirrhosis (SAFE or BA for F4). Therefore, in clinical practice, physicians have to apply the algorithm for F ≥ 2, and then, when needed, the algorithm for F4 ("successive algorithms"). We aimed to evaluate successive SAFE, successive BA, and a new, noninvasive, detailed classification of fibrosis. The study included 1785 patients with chronic hepatitis C, liver biopsy, blood fibrosis tests, and FibroScan (the latter in 729 patients). The most accurate synchronous combination of FibroScan with a blood test (FibroMeter) provided a new detailed (six classes) classification (FM+FS). Successive SAFE had a significantly (P < 10(-3) ) lower diagnostic accuracy (87.3%) than individual SAFE for F ≥ 2 (94.6%) or SAFE for F4 (89.5%), and required significantly more biopsies (70.8% versus 64.0% or 6.4%, respectively, P < 10(-3) ). Similarly, successive BA had significantly (P ≤ 10(-3) ) lower diagnostic accuracy (84.7%) than individual BA for F ≥ 2 (88.3%) or BA for F4 (94.2%), and required significantly more biopsies (49.8% versus 34.6% or 24.6%, respectively, P < 10(-3) ). The diagnostic accuracy of the FM+FS classification (86.7%) was not significantly different from those of successive SAFE or BA. However, this new classification required no biopsy. CONCLUSION: SAFE and BA for significant fibrosis or cirrhosis are very accurate. However, their successive use induces a significant decrease in diagnostic accuracy and a significant increase in required liver biopsy. A new fibrosis classification that synchronously combines two fibrosis tests was as accurate as successive SAFE or BA, while providing an entirely noninvasive (0% liver biopsy) and more precise (six versus two or three fibrosis classes) fibrosis diagnosis. The sequential algorithm for fibrosis evaluation (SAFE) and the Bordeaux algorithm (BA), which cross-check FibroTest with the aspartate aminotransferase-to-platelet ratio index (APRI) or FibroScan, are very accurate but provide only a binary diagnosis of significant fibrosis (SAFE or BA for Metavir F ≥ 2) or cirrhosis (SAFE or BA for F4). Therefore, in clinical practice, physicians have to apply the algorithm for F ≥ 2, and then, when needed, the algorithm for F4 ("successive algorithms"). We aimed to evaluate successive SAFE, successive BA, and a new, noninvasive, detailed classification of fibrosis. The study included 1785 patients with chronic hepatitis C, liver biopsy, blood fibrosis tests, and FibroScan (the latter in 729 patients). The most accurate synchronous combination of FibroScan with a blood test (FibroMeter) provided a new detailed (six classes) classification (FM+FS). Successive SAFE had a significantly (P < 10(-3) ) lower diagnostic accuracy (87.3%) than individual SAFE for F ≥ 2 (94.6%) or SAFE for F4 (89.5%), and required significantly more biopsies (70.8% versus 64.0% or 6.4%, respectively, P < 10(-3) ). Similarly, successive BA had significantly (P ≤ 10(-3) ) lower diagnostic accuracy (84.7%) than individual BA for F ≥ 2 (88.3%) or BA for F4 (94.2%), and required significantly more biopsies (49.8% versus 34.6% or 24.6%, respectively, P < 10(-3) ). The diagnostic accuracy of the FM+FS classification (86.7%) was not significantly different from those of successive SAFE or BA. However, this new classification required no biopsy. SAFE and BA for significant fibrosis or cirrhosis are very accurate. However, their successive use induces a significant decrease in diagnostic accuracy and a significant increase in required liver biopsy. A new fibrosis classification that synchronously combines two fibrosis tests was as accurate as successive SAFE or BA, while providing an entirely noninvasive (0% liver biopsy) and more precise (six versus two or three fibrosis classes) fibrosis diagnosis. The sequential algorithm for fibrosis evaluation (SAFE) and the Bordeaux algorithm (BA), which cross‐check FibroTest with the aspartate aminotransferase‐to‐platelet ratio index (APRI) or FibroScan, are very accurate but provide only a binary diagnosis of significant fibrosis (SAFE or BA for Metavir F ≥ 2) or cirrhosis (SAFE or BA for F4). Therefore, in clinical practice, physicians have to apply the algorithm for F ≥ 2, and then, when needed, the algorithm for F4 (“successive algorithms”). We aimed to evaluate successive SAFE, successive BA, and a new, noninvasive, detailed classification of fibrosis. The study included 1785 patients with chronic hepatitis C, liver biopsy, blood fibrosis tests, and FibroScan (the latter in 729 patients). The most accurate synchronous combination of FibroScan with a blood test (FibroMeter) provided a new detailed (six classes) classification (FM+FS). Successive SAFE had a significantly (P < 10−3) lower diagnostic accuracy (87.3%) than individual SAFE for F ≥ 2 (94.6%) or SAFE for F4 (89.5%), and required significantly more biopsies (70.8% versus 64.0% or 6.4%, respectively, P < 10−3). Similarly, successive BA had significantly (P ≤ 10−3) lower diagnostic accuracy (84.7%) than individual BA for F ≥ 2 (88.3%) or BA for F4 (94.2%), and required significantly more biopsies (49.8% versus 34.6% or 24.6%, respectively, P < 10−3). The diagnostic accuracy of the FM+FS classification (86.7%) was not significantly different from those of successive SAFE or BA. However, this new classification required no biopsy. Conclusion: SAFE and BA for significant fibrosis or cirrhosis are very accurate. However, their successive use induces a significant decrease in diagnostic accuracy and a significant increase in required liver biopsy. A new fibrosis classification that synchronously combines two fibrosis tests was as accurate as successive SAFE or BA, while providing an entirely noninvasive (0% liver biopsy) and more precise (six versus two or three fibrosis classes) fibrosis diagnosis. (HEPATOLOGY 2012;55:58–67) |
| Author | de Ledinghen, Victor Oberti, Frédéric Zarski, Jean-Pierre Fouchard-Hubert, Isabelle Boursier, Jérôme Gallois, Yves Calès, Paul |
| Author_xml | – sequence: 1 givenname: Jérôme surname: Boursier fullname: Boursier, Jérôme email: JeBoursier@chu-angers.fr organization: Department of Hepatogastroenterology, University Hospital, Angers, France – sequence: 2 givenname: Victor surname: de Ledinghen fullname: de Ledinghen, Victor organization: Department of Hepatogastroenterology, Haut-Lévêque University Hospital, Pessac, France – sequence: 3 givenname: Jean-Pierre surname: Zarski fullname: Zarski, Jean-Pierre organization: Department of Liver-Gastroenterology, University Hospital, Grenoble, France – sequence: 4 givenname: Isabelle surname: Fouchard-Hubert fullname: Fouchard-Hubert, Isabelle organization: Department of Hepatogastroenterology, University Hospital, Angers, France – sequence: 5 givenname: Yves surname: Gallois fullname: Gallois, Yves organization: HIFIH Laboratory, UPRES 3859, Institut Fédératif de Recherche (IFR) 132, University of Angers, Pôle de Recherche et d'Enseignement Supérieur Université Nantes Angers Le Mans (PRES UNAM), France – sequence: 6 givenname: Frédéric surname: Oberti fullname: Oberti, Frédéric organization: Department of Hepatogastroenterology, University Hospital, Angers, France – sequence: 7 givenname: Paul surname: Calès fullname: Calès, Paul organization: Department of Hepatogastroenterology, University Hospital, Angers, France |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25543199$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/21898504$$D View this record in MEDLINE/PubMed https://hal.science/hal-00866967$$DView record in HAL |
| BookMark | eNp90ltv0zAUB_AIDbELPPAFkCWEgIdsvsYxb1M1VlDFReLyaJ06TuuR2MVOO_oB-N64tOvQJPYSK9Hvf5zj4-PiwAdvi-IpwacEY3o2t4tTyivBHxRHRFBZMibwQXGEqcSlIkwdFscpXWGMFaf1o-KQklrVAvOj4vco9AuILgWPQousm80H1DiY-ZAGZxB0sxDdMO8TakNEnVvZiFo3jSG5hJxHeW8Y3JBfRm-Qt9f_JiBa1If8WERrXLIIfIOsH1y03RrlJpxfQcolHxcPW-iSfbJbT4qvby--jMbl5OPlu9H5pDS8lrxU1MgazJQJQlpGiVTcWGWAV4bLBmoDtgZBFCEUS8MkZ7USkliwTSMaQthJ8Xpbdw6dXkTXQ1zrAE6Pzyd68w3juqpUJVcb-3JrFzH8XNo06N4lY7sOvA3LpBWhFVNciixf3SuJlFVV1YKqTJ_foVdhGX3uOatsqGCCZvVsp5bT3jb7P70ZWwYvdgCSga6N4PP53johOCNK3fZr8rxStO2eEKw3V0fn8em_VyfbszvWuCGPNvghguvuS1y7zq7_X1qPLz7dJMptwqXB_tonIP7QlWRS6O8fLjVjY_4N88_6PfsDc6HikA |
| CODEN | HPTLD9 |
| CitedBy_id | crossref_primary_10_1016_j_jhep_2019_04_020 crossref_primary_10_1016_j_cmi_2016_09_017 crossref_primary_10_1016_j_dld_2018_11_016 crossref_primary_10_1111_liv_12327 crossref_primary_10_1111_liv_13536 crossref_primary_10_1016_S0973_6883_12_60077_2 crossref_primary_10_17816_0869_2106_2021_27_4_373_384 crossref_primary_10_1016_j_cegh_2020_04_011 crossref_primary_10_3389_fphar_2021_734090 crossref_primary_10_1016_j_critrevonc_2013_07_005 crossref_primary_10_1002_hep_25993 crossref_primary_10_4254_wjh_v9_i6_310 crossref_primary_10_1016_j_jhep_2024_04_007 crossref_primary_10_1016_j_ijmedinf_2024_105373 crossref_primary_10_19163_2307_9266_2019_7_6_356_362 crossref_primary_10_1517_17530059_2012_691878 crossref_primary_10_1016_S1665_2681_19_31456_5 crossref_primary_10_1002_hep4_1161 crossref_primary_10_1016_j_jhep_2017_02_011 crossref_primary_10_1016_j_jhep_2016_04_023 crossref_primary_10_1186_s12876_022_02108_0 crossref_primary_10_1038_srep01065 crossref_primary_10_1097_MEG_0000000000000346 crossref_primary_10_1007_s10620_023_08085_y crossref_primary_10_1136_bmjgast_2019_000316 crossref_primary_10_1136_gutjnl_2018_317593 crossref_primary_10_1111_apt_13954 crossref_primary_10_1155_2024_5540648 crossref_primary_10_3748_wjg_v22_i4_1367 crossref_primary_10_3310_hta19090 crossref_primary_10_3389_fphar_2016_00159 crossref_primary_10_1111_jvh_13548 crossref_primary_10_1016_j_jhep_2016_10_006 crossref_primary_10_1016_j_jhep_2017_01_003 crossref_primary_10_1002_hep_25517 crossref_primary_10_3390_transplantology4020008 crossref_primary_10_1007_s10620_015_3682_0 crossref_primary_10_2463_mrms_2014_0150 crossref_primary_10_1016_j_jhep_2014_02_029 crossref_primary_10_5604_01_3001_0009_8589 crossref_primary_10_1007_s11377_015_0034_8 crossref_primary_10_1371_journal_pone_0173506 crossref_primary_10_2217_cpr_12_18 crossref_primary_10_4254_wjh_v10_i1_105 crossref_primary_10_3748_wjg_v22_i29_6663 crossref_primary_10_4103_2153_3539_157782 crossref_primary_10_1128_CMR_00037_16 crossref_primary_10_4103_ejim_ejim_46_19 crossref_primary_10_1016_S0140_6736_15_00349_9 crossref_primary_10_1097_SGA_0000000000000430 crossref_primary_10_1016_S2468_1253_17_30116_4 crossref_primary_10_1002_hep_26144 crossref_primary_10_1111_apt_15529 crossref_primary_10_1002_hep_27950 crossref_primary_10_1097_RUQ_0000000000000209 crossref_primary_10_1016_j_cgh_2015_07_030 crossref_primary_10_1097_MCG_0b013e318266fe70 crossref_primary_10_1097_MEG_0000000000000182 crossref_primary_10_1097_MCG_0000000000000788 crossref_primary_10_1111_j_1365_2516_2012_02854_x crossref_primary_10_1016_j_jhep_2015_04_006 crossref_primary_10_14218_JCTH_2017_00038 crossref_primary_10_1053_j_gastro_2012_02_017 crossref_primary_10_1093_bmb_ldu031 crossref_primary_10_1016_j_jhepr_2020_100067 crossref_primary_10_1007_s40265_019_01126_9 crossref_primary_10_1148_radiol_2015150619 crossref_primary_10_1148_radiol_231220 crossref_primary_10_5812_hepatmon_6229 crossref_primary_10_1097_HEP_0000000000000843 crossref_primary_10_1097_01_NPR_0000515423_38284_28 crossref_primary_10_1146_annurev_physiol_021115_105331 crossref_primary_10_1016_j_clinre_2012_08_002 crossref_primary_10_7326_M15_0785 crossref_primary_10_1136_gutjnl_2020_322976 crossref_primary_10_1111_hepr_12696 crossref_primary_10_1093_cid_cit245 crossref_primary_10_1155_2015_809289 crossref_primary_10_5812_hepatmon_5106 crossref_primary_10_1007_s11606_017_4280_y crossref_primary_10_1186_s12967_016_0952_3 crossref_primary_10_3748_wjg_v20_i32_11033 crossref_primary_10_1159_000374097 crossref_primary_10_3892_mmr_2015_3299 crossref_primary_10_1007_s10620_012_2153_0 crossref_primary_10_1111_jvh_12310 crossref_primary_10_4291_wjgp_v12_i3_40 crossref_primary_10_1016_j_dld_2015_02_001 crossref_primary_10_1016_j_numecd_2021_04_016 |
| Cites_doi | 10.1002/hep.22859 10.1016/j.jhep.2006.09.020 10.1097/MEG.0b013e32830cebd7 10.1016/j.gcb.2008.09.017 10.1053/j.gastro.2004.11.018 10.1111/j.1478-3231.2008.01789.x 10.1016/j.clinbiochem.2008.06.020 10.1002/hep.22748 10.1111/j.1478-3231.2009.02101.x 10.1002/hep.22375 10.1038/ajg.2011.100 10.1016/j.jhep.2008.07.039 10.1016/j.clinbiochem.2007.08.009 10.1016/j.jhep.2006.01.007 10.1111/j.1365-2036.2008.03742.x 10.1016/j.cgh.2009.01.010 10.1016/j.jhep.2009.11.008 10.1053/jhep.2003.50346 10.1111/j.1365-2893.2006.00736.x 10.1016/j.jhep.2008.02.008 10.1002/hep.23185 10.1002/hep.23069 10.1016/j.jhep.2008.10.014 |
| ContentType | Journal Article |
| Contributor | de Ledinghen, Victor Lunel, Françoise Merrouche, Wassil Bioulac-Sage, Paulette Bréchot, Marie-Claude Danielou, H Marcellin, P Guyader, D Garcia, Stéphane Trocme, Candice Rogeaux, O Faure, Patrice Asselah, T Lavoinne, A Bronowicki, J P Beaugrand, M Penaranda, Guillaume Tran, Albert Rosenthal-Allieri, A Paradis, Valérie Poujol, A Bourliere, M Lasnier, R Maynard-Muet, M Bourlière, Marc Pottier, A Michalak, Sophie Tran, A Ouzan, Denis Leroy, Vincent Metivier, S Pol, S Habersetzer, F Chevailler, Alain Couzigou, Patrice Degott, Claude Gelineau, M-C Bartoli, M Myara, A Sturm, Nathalie Renversez, Jean-Charles Poupon, R de Muret, Anne Morel, Francoise Vassault, A Abergel, A Leroy, V Poggi, B Bonneau, Henri Pierre Castéra, Laurent Trepo, C Saint-Paul, Marie-Christine De Ledinghen, V Vaubourdolle, M Le Bail, Brigitte Goria, O Voitot, H Foucher, Juliette Mathurin, Ph Hilleret, M N Guerber, F Larrey, D Mansour, Wael Benderitter, Thierry Ziegler, F Ternisien, Catherine Halfon, Philippe Renou, Christophe Bacq, Yannick Boisson, R-C Botta, Danielle Oulès, V Bernard, Pierre |
| Contributor_xml | – sequence: 1 givenname: Sophie surname: Michalak fullname: Michalak, Sophie – sequence: 2 givenname: Anselme surname: Konaté fullname: Konaté, Anselme – sequence: 3 givenname: Catherine surname: Ternisien fullname: Ternisien, Catherine – sequence: 4 givenname: Alain surname: Chevailler fullname: Chevailler, Alain – sequence: 5 givenname: Françoise surname: Lunel fullname: Lunel, Françoise – sequence: 6 givenname: Marie Christine surname: Rousselet fullname: Rousselet, Marie Christine – sequence: 7 givenname: Wael surname: Mansour fullname: Mansour, Wael – sequence: 8 givenname: Philippe surname: Halfon fullname: Halfon, Philippe – sequence: 9 givenname: Marc surname: Bourlière fullname: Bourlière, Marc – sequence: 10 givenname: Denis surname: Ouzan fullname: Ouzan, Denis – sequence: 11 givenname: Albert surname: Tran fullname: Tran, Albert – sequence: 12 givenname: Danielle surname: Botta fullname: Botta, Danielle – sequence: 13 givenname: Christophe surname: Renou fullname: Renou, Christophe – sequence: 14 givenname: Christophe surname: Sattonnet fullname: Sattonnet, Christophe – sequence: 15 givenname: Marie-Christine surname: Saint-Paul fullname: Saint-Paul, Marie-Christine – sequence: 16 givenname: Thierry surname: Benderitter fullname: Benderitter, Thierry – sequence: 17 givenname: Stéphane surname: Garcia fullname: Garcia, Stéphane – sequence: 18 givenname: Henri Pierre surname: Bonneau fullname: Bonneau, Henri Pierre – sequence: 19 givenname: Guillaume surname: Penaranda fullname: Penaranda, Guillaume – sequence: 20 givenname: Yannick surname: Bacq fullname: Bacq, Yannick – sequence: 21 givenname: Anne surname: de Muret fullname: de Muret, Anne – sequence: 22 givenname: Marie-Claude surname: Bréchot fullname: Bréchot, Marie-Claude – sequence: 23 givenname: Vincent surname: Leroy fullname: Leroy, Vincent – sequence: 24 givenname: Nathalie surname: Sturm fullname: Sturm, Nathalie – sequence: 25 givenname: Marie-Noelle surname: Hilleret fullname: Hilleret, Marie-Noelle – sequence: 26 givenname: Patrice surname: Faure fullname: Faure, Patrice – sequence: 27 givenname: Jean-Charles surname: Renversez fullname: Renversez, Jean-Charles – sequence: 28 givenname: Francoise surname: Morel fullname: Morel, Francoise – sequence: 29 givenname: Candice surname: Trocme fullname: Trocme, Candice – sequence: 30 givenname: Victor surname: de Ledinghen fullname: de Ledinghen, Victor – sequence: 31 givenname: Juliette surname: Foucher fullname: Foucher, Juliette – sequence: 32 givenname: Laurent surname: Castéra fullname: Castéra, Laurent – sequence: 33 givenname: Patrice surname: Couzigou fullname: Couzigou, Patrice – sequence: 34 givenname: Pierre-Henri surname: Bernard fullname: Bernard, Pierre-Henri – sequence: 35 givenname: Wassil surname: Merrouche fullname: Merrouche, Wassil – sequence: 36 givenname: Paulette surname: Bioulac-Sage fullname: Bioulac-Sage, Paulette – sequence: 37 givenname: Brigitte surname: Le Bail fullname: Le Bail, Brigitte – sequence: 38 givenname: Claude surname: Degott fullname: Degott, Claude – sequence: 39 givenname: Valérie surname: Paradis fullname: Paradis, Valérie – sequence: 40 givenname: R surname: Poupon fullname: Poupon, R – sequence: 41 givenname: A surname: Poujol fullname: Poujol, A – sequence: 42 givenname: A surname: Abergel fullname: Abergel, A – sequence: 43 givenname: J P surname: Bronowicki fullname: Bronowicki, J P – sequence: 44 givenname: J P surname: Vinel fullname: Vinel, J P – sequence: 45 givenname: S surname: Metivier fullname: Metivier, S – sequence: 46 givenname: V surname: De Ledinghen fullname: De Ledinghen, V – sequence: 47 givenname: J surname: Foucher fullname: Foucher, J – sequence: 48 givenname: O surname: Goria fullname: Goria, O – sequence: 49 givenname: M surname: Maynard-Muet fullname: Maynard-Muet, M – sequence: 50 givenname: C surname: Trepo fullname: Trepo, C – sequence: 51 givenname: Ph surname: Mathurin fullname: Mathurin, Ph – sequence: 52 givenname: D surname: Guyader fullname: Guyader, D – sequence: 53 givenname: H surname: Danielou fullname: Danielou, H – sequence: 54 givenname: O surname: Rogeaux fullname: Rogeaux, O – sequence: 55 givenname: S surname: Pol fullname: Pol, S – sequence: 56 givenname: Ph surname: Sogni fullname: Sogni, Ph – sequence: 57 givenname: A surname: Tran fullname: Tran, A – sequence: 58 givenname: P surname: Calès fullname: Calès, P – sequence: 59 givenname: P surname: Marcellin fullname: Marcellin, P – sequence: 60 givenname: T surname: Asselah fullname: Asselah, T – sequence: 61 givenname: M surname: Bourliere fullname: Bourliere, M – sequence: 62 givenname: V surname: Oulès fullname: Oulès, V – sequence: 63 givenname: D surname: Larrey fullname: Larrey, D – sequence: 64 givenname: F surname: Habersetzer fullname: Habersetzer, F – sequence: 65 givenname: M surname: Beaugrand fullname: Beaugrand, M – sequence: 66 givenname: V surname: Leroy fullname: Leroy, V – sequence: 67 givenname: M N surname: Hilleret fullname: Hilleret, M N – sequence: 68 givenname: R-C surname: Boisson fullname: Boisson, R-C – sequence: 69 givenname: M-C surname: Gelineau fullname: Gelineau, M-C – sequence: 70 givenname: B surname: Poggi fullname: Poggi, B – sequence: 71 givenname: J-C surname: Renversez fullname: Renversez, J-C – sequence: 72 givenname: Candice surname: Trocmé fullname: Trocmé, Candice – sequence: 73 givenname: J surname: Guéchot fullname: Guéchot, J – sequence: 74 givenname: R surname: Lasnier fullname: Lasnier, R – sequence: 75 givenname: M surname: Vaubourdolle fullname: Vaubourdolle, M – sequence: 76 givenname: H surname: Voitot fullname: Voitot, H – sequence: 77 givenname: A surname: Vassault fullname: Vassault, A – sequence: 78 givenname: A surname: Rosenthal-Allieri fullname: Rosenthal-Allieri, A – sequence: 79 givenname: A surname: Lavoinne fullname: Lavoinne, A – sequence: 80 givenname: F surname: Ziegler fullname: Ziegler, F – sequence: 81 givenname: M surname: Bartoli fullname: Bartoli, M – sequence: 82 givenname: C surname: Lebrun fullname: Lebrun, C – sequence: 83 givenname: A surname: Myara fullname: Myara, A – sequence: 84 givenname: F surname: Guerber fullname: Guerber, F – sequence: 85 givenname: A surname: Pottier fullname: Pottier, A |
| Copyright | Copyright © 2011 American Association for the Study of Liver Diseases 2015 INIST-CNRS Copyright © 2011 American Association for the Study of Liver Diseases. Distributed under a Creative Commons Attribution 4.0 International License |
| Copyright_xml | – notice: Copyright © 2011 American Association for the Study of Liver Diseases – notice: 2015 INIST-CNRS – notice: Copyright © 2011 American Association for the Study of Liver Diseases. – notice: Distributed under a Creative Commons Attribution 4.0 International License |
| CorporateAuthor | multicentric groups from SNIFF 32, VINDIAG 7, and ANRS/HC/EP23 FIBROSTAR studies |
| CorporateAuthor_xml | – name: multicentric groups from SNIFF 32, VINDIAG 7, and ANRS/HC/EP23 FIBROSTAR studies |
| DBID | BSCLL AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7T5 7TM 7TO 7U9 H94 K9. 7X8 1XC |
| DOI | 10.1002/hep.24654 |
| DatabaseName | Istex CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic Hyper Article en Ligne (HAL) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts Nucleic Acids Abstracts MEDLINE - Academic |
| DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE - Academic AIDS and Cancer Research Abstracts MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1527-3350 |
| EndPage | 67 |
| ExternalDocumentID | oai:HAL:hal-00866967v1 3958148881 21898504 25543199 10_1002_hep_24654 HEP24654 ark_67375_WNG_33H4V04Q_J |
| Genre | article Validation Studies Comparative Study Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Program Hospitalier de Recherche Clinique (PHRC) – fundername: French Department of Health in 1994 and 2002 for SNIFF 32 – fundername: Agence National de Recherche sur le Sida et les Hépatites (ANRS) – fundername: FIBROSTAR HC/EP23 |
| GroupedDBID | --- --K .3N .55 .GA .GJ .Y3 05W 0R~ 10A 186 1B1 1CY 1L6 1OC 1ZS 1~5 31~ 33P 3O- 3SF 3WU 4.4 4G. 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5RE 5VS 7-5 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAEDT AAESR AAEVG AALRI AAMMB AANHP AAONW AAQFI AAQQT AAQXK AASGY AAXRX AAXUO AAZKR ABCQN ABCUV ABEML ABIJN ABJNI ABLJU ABMAC ABOCM ABPVW ABWVN ABXGK ACAHQ ACBWZ ACCZN ACGFS ACLDA ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ACZKN ADBBV ADEOM ADIZJ ADKYN ADMGS ADMUD ADNMO ADOZA ADSXY ADXAS ADZMN AECAP AEFGJ AEIMD AENEX AFBPY AFFNX AFGKR AFNMH AFUWQ AFZJQ AGQPQ AGXDD AHMBA AHQVU AIACR AIDQK AIDYY AIQQE AIURR AJAOE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EBS EJD F00 F01 F04 F5P FD8 FDB FEDTE FGOYB FUBAC G-S G.N GNP GODZA H.X HBH HF~ HHY HHZ HVGLF HZ~ IHE IX1 J0M J5H JPC KBYEO KQQ LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M41 M65 MEWTI MJL MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N4W N9A NF~ NNB NQ- O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K R2- RIG RIWAO RJQFR ROL RPZ RX1 RYL SEW SSZ SUPJJ TEORI UB1 V2E V9Y W2D W8V W99 WBKPD WH7 WHWMO WIB WIH WIJ WIK WJL WOHZO WQJ WVDHM WXI WXSBR X7M XG1 XV2 ZGI ZXP ZZTAW ~IA ~WT 1OB 24P AAHHS ACCFJ ADZOD AEEZP AEQDE AEUQT AFPWT AIWBW AJBDE RGB RWI WIN WRC WUP AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7T5 7TM 7TO 7U9 H94 K9. 7X8 1XC |
| ID | FETCH-LOGICAL-c4874-92c78acb3511f321794ce9ca46c47da8cae8a51911207c374389571eaedd5d113 |
| IEDL.DBID | DR2 |
| ISSN | 0270-9139 1527-3350 |
| IngestDate | Thu Oct 30 06:51:09 EDT 2025 Thu Jul 10 23:51:22 EDT 2025 Wed Oct 01 14:12:30 EDT 2025 Tue Oct 07 05:54:31 EDT 2025 Mon Jul 21 06:06:04 EDT 2025 Mon Jul 21 09:16:17 EDT 2025 Wed Oct 01 04:12:58 EDT 2025 Thu Apr 24 23:10:07 EDT 2025 Wed Jan 22 16:21:19 EST 2025 Sun Sep 21 06:17:15 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Infection Hepatic fibrosis Viral disease Gastroenterology Digestive diseases Hepatic disease Diagnosis Algorithm Comparative study Viral hepatitis C |
| Language | English |
| License | CC BY 4.0 Copyright © 2011 American Association for the Study of Liver Diseases. Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4874-92c78acb3511f321794ce9ca46c47da8cae8a51911207c374389571eaedd5d113 |
| Notes | Program Hospitalier de Recherche Clinique (PHRC) Potential conflict of interest: P.C., I.F.H., and F.O. have stock ownership in BioLiveScale Inc., which has a license for FibroMeter from the University of Angers. FIBROSTAR HC/EP23 French Department of Health in 1994 and 2002 for SNIFF 32 Agence National de Recherche sur le Sida et les Hépatites (ANRS) Supported by the Program Hospitalier de Recherche Clinique (PHRC) of the French Department of Health in 1994 and 2002 for SNIFF 32 and the Agence National de Recherche sur le Sida et les Hépatites (ANRS) for FIBROSTAR HC/EP23. istex:0A54D214C6902F0B45226975325AF12159FFE6B6 ArticleID:HEP24654 ark:/67375/WNG-33H4V04Q-J fax: (33) 2 41 35 41 19 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 ObjectType-Undefined-3 |
| ORCID | 0000-0001-6414-1951 0000-0003-4866-5274 |
| PMID | 21898504 |
| PQID | 1766825352 |
| PQPubID | 996352 |
| PageCount | 10 |
| ParticipantIDs | hal_primary_oai_HAL_hal_00866967v1 proquest_miscellaneous_912639475 proquest_miscellaneous_1776668529 proquest_journals_1766825352 pubmed_primary_21898504 pascalfrancis_primary_25543199 crossref_primary_10_1002_hep_24654 crossref_citationtrail_10_1002_hep_24654 wiley_primary_10_1002_hep_24654_HEP24654 istex_primary_ark_67375_WNG_33H4V04Q_J |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2012-01 January 2012 2012-01-00 2012 2012-Jan 20120101 |
| PublicationDateYYYYMMDD | 2012-01-01 |
| PublicationDate_xml | – month: 01 year: 2012 text: 2012-01 |
| PublicationDecade | 2010 |
| PublicationPlace | Hoboken |
| PublicationPlace_xml | – name: Hoboken – name: Hoboken, NJ – name: United States |
| PublicationTitle | Hepatology (Baltimore, Md.) |
| PublicationTitleAlternate | Hepatology |
| PublicationYear | 2012 |
| Publisher | Wiley Subscription Services, Inc., A Wiley Company Wiley Wolters Kluwer Health, Inc Wiley-Blackwell |
| Publisher_xml | – name: Wiley Subscription Services, Inc., A Wiley Company – name: Wiley – name: Wolters Kluwer Health, Inc – name: Wiley-Blackwell |
| References | Cales P, De Ledinghen V, Halfon P, Bacq Y, Leroy V, Boursier J, et al. Evaluating accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C. Liver Int 2008; 28: 1352-1362. Zarski H, Sturm N, Guechot J, Paris A. Independent and prospective comparison of 9 surrogate markers for the diagnosis of liver fibrosis in chronic hepatitis C [Abstract]. Hepatology 2009; 50( Suppl 4): 1061A. Halfon P, Bacq Y, De Muret A, Penaranda G, Bourliere M, Ouzan D, et al. Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. J Hepatol 2007; 46: 395-402. Mehta SH, Lau B, Afdhal NH, Thomas DL. Exceeding the limits of liver histology markers. J Hepatol 2009; 50: 36-41. Sebastiani G, Vario A, Guido M, Noventa F, Plebani M, Pistis R, et al. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol 2006; 44: 686-693. Castera L, Sebastiani G, Le Bail B, de Ledinghen V, Couzigou P, Alberti A. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol 2010; 52: 191-198. Bourliere M, Penaranda G, Renou C, Botta-Fridlund D, Tran A, Portal I, et al. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies. J Viral Hepat 2006; 13: 659-670. Boursier J, Cales P. Combination of fibrosis tests: sequential or synchronous? Hepatology 2009; 50: 656-657. Cales P, Veillon P, Konate A, Mathieu E, Ternisien C, Chevailler A, et al. Reproducibility of blood tests of liver fibrosis in clinical practice. Clin Biochem 2008; 41: 10-18. Boursier J, De Ledinghen V, Zarski J, Rousselet MC, Sturm N, Foucher J, et al. A new combination of blood test and Fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C. Am J Gastroenterol 2011; 106: 1255-1263. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48: 418-431. Bourliere M, Penaranda G, Ouzan D, Renou C, Botta-Fridlund D, Tran A, et al. Optimized stepwise combination algorithms of non-invasive liver fibrosis scores including Hepascore in hepatitis C virus patients. Aliment Pharmacol Ther 2008; 28: 458-467. Leroy V, Halfon P, Bacq Y, Boursier J, Rousselet MC, Bourliere M, et al. Diagnostic accuracy, reproducibility and robustness of fibrosis blood tests in chronic hepatitis C: a meta-analysis with individual data. Clin Biochem 2008; 41: 1368-1376. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-350. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48: 835-847. Cales P, Boursier J, de Ledinghen V, Halfon P, Bacq Y, Leroy V, et al. Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests. Gastroenterol Clin Biol 2008; 32: 1050-1060. Lucidarme D, Foucher J, Le Bail B, Vergniol J, Castera L, Duburque C, et al. Factors of accuracy of transient elastography (Fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C. Hepatology 2009; 49: 1083-1089. Boursier J, Bacq Y, Halfon P, Leroy V, De Ledinghen V, De Muret A, et al. Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C. Eur J Gastroenterol Hepatol 2009; 21: 28-38. Becker L, Salameh W, Sferruzza A, Zhang K, Chen R, Malik R, et al. Validation of Hepascore, compared to simple indices of fibrosis, in US patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2009; 7: 696-701. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526. Rashid M, Mitchell JD, Cramp ME, Cross TJ. Limitations of the algorithm for the SAFE biopsy: a noninvasive fibrosis measure in chronic hepatitis C. Hepatology 2010; 51: 354-355. Boursier J, Vergniol J, Sawadogo A, Dakka T, Michalak S, Gallois Y, et al. The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis. Liver Int 2009; 29: 1507-1515. Bedossa P, Carrat F. Liver biopsy: the best, not the gold standard. J Hepatol 2009; 50: 1-3. Sebastiani G, Halfon P, Castera L, Pol S, Thomas DL, Mangia A, et al. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology 2009; 49: 1821-1827. 2009; 21 2011; 106 2006; 13 2009; 50 2006; 44 2005; 128 2008; 28 2008; 48 2003; 38 2009; 7 2008; 32 2008; 41 2009; 49 2010; 52 2007; 46 2010; 51 2009; 29 Zarski (R15-9-20241201) 2009; 50 Cales (R13-9-20241201) 2008; 28 Sebastiani (R2-9-20241201) 2006; 44 Castera (R1-9-20241201) 2005; 128 Mehta (R24-9-20241201) 2009; 50 Bedossa (R23-9-20241201) 2009; 50 Sebastiani (R6-9-20241201) 2009; 49 Cales (R12-9-20241201) 2008; 32 Bourliere (R3-9-20241201) 2006; 13 Boursier (R10-9-20241201) 2009; 21 Boursier (R11-9-20241201) 2009; 50 Wai (R17-9-20241201) 2003; 38 Thein (R22-9-20241201) 2008; 48 Becker (R5-9-20241201) 2009; 7 Rashid (R9-9-20241201) 2010; 51 Castera (R7-9-20241201) 2010; 52 Boursier (R8-9-20241201) 2009; 29 Cales (R18-9-20241201) 2008; 41 Leroy (R16-9-20241201) 2008; 41 Bourliere (R4-9-20241201) 2008; 28 Boursier (R14-9-20241201) 2011; 106 Castera (R19-9-20241201) 2008; 48 Lucidarme (R20-9-20241201) 2009; 49 Halfon (R21-9-20241201) 2007; 46 22162013 - Hepatology. 2012 Feb;55(2):652-3; author reply 653 |
| References_xml | – reference: Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48: 835-847. – reference: Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-350. – reference: Boursier J, Cales P. Combination of fibrosis tests: sequential or synchronous? Hepatology 2009; 50: 656-657. – reference: Boursier J, Vergniol J, Sawadogo A, Dakka T, Michalak S, Gallois Y, et al. The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis. Liver Int 2009; 29: 1507-1515. – reference: Boursier J, Bacq Y, Halfon P, Leroy V, De Ledinghen V, De Muret A, et al. Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C. Eur J Gastroenterol Hepatol 2009; 21: 28-38. – reference: Halfon P, Bacq Y, De Muret A, Penaranda G, Bourliere M, Ouzan D, et al. Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. J Hepatol 2007; 46: 395-402. – reference: Boursier J, De Ledinghen V, Zarski J, Rousselet MC, Sturm N, Foucher J, et al. A new combination of blood test and Fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C. Am J Gastroenterol 2011; 106: 1255-1263. – reference: Mehta SH, Lau B, Afdhal NH, Thomas DL. Exceeding the limits of liver histology markers. J Hepatol 2009; 50: 36-41. – reference: Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48: 418-431. – reference: Cales P, De Ledinghen V, Halfon P, Bacq Y, Leroy V, Boursier J, et al. Evaluating accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C. Liver Int 2008; 28: 1352-1362. – reference: Castera L, Sebastiani G, Le Bail B, de Ledinghen V, Couzigou P, Alberti A. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol 2010; 52: 191-198. – reference: Lucidarme D, Foucher J, Le Bail B, Vergniol J, Castera L, Duburque C, et al. Factors of accuracy of transient elastography (Fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C. Hepatology 2009; 49: 1083-1089. – reference: Sebastiani G, Halfon P, Castera L, Pol S, Thomas DL, Mangia A, et al. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology 2009; 49: 1821-1827. – reference: Rashid M, Mitchell JD, Cramp ME, Cross TJ. Limitations of the algorithm for the SAFE biopsy: a noninvasive fibrosis measure in chronic hepatitis C. Hepatology 2010; 51: 354-355. – reference: Leroy V, Halfon P, Bacq Y, Boursier J, Rousselet MC, Bourliere M, et al. Diagnostic accuracy, reproducibility and robustness of fibrosis blood tests in chronic hepatitis C: a meta-analysis with individual data. Clin Biochem 2008; 41: 1368-1376. – reference: Becker L, Salameh W, Sferruzza A, Zhang K, Chen R, Malik R, et al. Validation of Hepascore, compared to simple indices of fibrosis, in US patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2009; 7: 696-701. – reference: Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526. – reference: Bedossa P, Carrat F. Liver biopsy: the best, not the gold standard. J Hepatol 2009; 50: 1-3. – reference: Bourliere M, Penaranda G, Renou C, Botta-Fridlund D, Tran A, Portal I, et al. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies. J Viral Hepat 2006; 13: 659-670. – reference: Bourliere M, Penaranda G, Ouzan D, Renou C, Botta-Fridlund D, Tran A, et al. Optimized stepwise combination algorithms of non-invasive liver fibrosis scores including Hepascore in hepatitis C virus patients. Aliment Pharmacol Ther 2008; 28: 458-467. – reference: Cales P, Boursier J, de Ledinghen V, Halfon P, Bacq Y, Leroy V, et al. Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests. Gastroenterol Clin Biol 2008; 32: 1050-1060. – reference: Zarski H, Sturm N, Guechot J, Paris A. Independent and prospective comparison of 9 surrogate markers for the diagnosis of liver fibrosis in chronic hepatitis C [Abstract]. Hepatology 2009; 50( Suppl 4): 1061A. – reference: Sebastiani G, Vario A, Guido M, Noventa F, Plebani M, Pistis R, et al. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol 2006; 44: 686-693. – reference: Cales P, Veillon P, Konate A, Mathieu E, Ternisien C, Chevailler A, et al. Reproducibility of blood tests of liver fibrosis in clinical practice. Clin Biochem 2008; 41: 10-18. – volume: 52 start-page: 191 year: 2010 end-page: 198 article-title: Prospective comparison of two algorithms combining non‐invasive methods for staging liver fibrosis in chronic hepatitis C publication-title: J Hepatol – volume: 21 start-page: 28 year: 2009 end-page: 38 article-title: Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C publication-title: Eur J Gastroenterol Hepatol – volume: 128 start-page: 343 year: 2005 end-page: 350 article-title: Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C publication-title: Gastroenterology – volume: 51 start-page: 354 year: 2010 end-page: 355 article-title: Limitations of the algorithm for the SAFE biopsy: a noninvasive fibrosis measure in chronic hepatitis C publication-title: Hepatology – volume: 7 start-page: 696 year: 2009 end-page: 701 article-title: Validation of Hepascore, compared to simple indices of fibrosis, in US patients with chronic hepatitis C virus infection publication-title: Clin Gastroenterol Hepatol – volume: 50 start-page: 1061A issue: Suppl 4 year: 2009 article-title: Independent and prospective comparison of 9 surrogate markers for the diagnosis of liver fibrosis in chronic hepatitis C [Abstract] publication-title: Hepatology – volume: 46 start-page: 395 year: 2007 end-page: 402 article-title: Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C publication-title: J Hepatol – volume: 50 start-page: 656 year: 2009 end-page: 657 article-title: Combination of fibrosis tests: sequential or synchronous? publication-title: Hepatology – volume: 41 start-page: 10 year: 2008 end-page: 18 article-title: Reproducibility of blood tests of liver fibrosis in clinical practice publication-title: Clin Biochem – volume: 28 start-page: 1352 year: 2008 end-page: 1362 article-title: Evaluating accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C publication-title: Liver Int – volume: 13 start-page: 659 year: 2006 end-page: 670 article-title: Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies publication-title: J Viral Hepat – volume: 106 start-page: 1255 year: 2011 end-page: 1263 article-title: A new combination of blood test and Fibroscan for accurate non‐invasive diagnosis of liver fibrosis stages in chronic hepatitis C publication-title: Am J Gastroenterol – volume: 29 start-page: 1507 year: 2009 end-page: 1515 article-title: The combination of a blood test and Fibroscan improves the non‐invasive diagnosis of liver fibrosis publication-title: Liver Int – volume: 41 start-page: 1368 year: 2008 end-page: 1376 article-title: Diagnostic accuracy, reproducibility and robustness of fibrosis blood tests in chronic hepatitis C: a meta‐analysis with individual data publication-title: Clin Biochem – volume: 50 start-page: 1 year: 2009 end-page: 3 article-title: Liver biopsy: the best, not the gold standard publication-title: J Hepatol – volume: 50 start-page: 36 year: 2009 end-page: 41 article-title: Exceeding the limits of liver histology markers publication-title: J Hepatol – volume: 44 start-page: 686 year: 2006 end-page: 693 article-title: Stepwise combination algorithms of non‐invasive markers to diagnose significant fibrosis in chronic hepatitis C publication-title: J Hepatol – volume: 49 start-page: 1821 year: 2009 end-page: 1827 article-title: SAFE biopsy: a validated method for large‐scale staging of liver fibrosis in chronic hepatitis C publication-title: Hepatology – volume: 48 start-page: 418 year: 2008 end-page: 431 article-title: Estimation of stage‐specific fibrosis progression rates in chronic hepatitis C virus infection: a meta‐analysis and meta‐regression publication-title: Hepatology – volume: 32 start-page: 1050 year: 2008 end-page: 1060 article-title: Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests publication-title: Gastroenterol Clin Biol – volume: 49 start-page: 1083 year: 2009 end-page: 1089 article-title: Factors of accuracy of transient elastography (Fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C publication-title: Hepatology – volume: 28 start-page: 458 year: 2008 end-page: 467 article-title: Optimized stepwise combination algorithms of non‐invasive liver fibrosis scores including Hepascore in hepatitis C virus patients publication-title: Aliment Pharmacol Ther – volume: 38 start-page: 518 year: 2003 end-page: 526 article-title: A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C publication-title: Hepatology – volume: 48 start-page: 835 year: 2008 end-page: 847 article-title: Non‐invasive evaluation of liver fibrosis using transient elastography publication-title: J Hepatol – volume: 49 start-page: 1821 year: 2009 ident: R6-9-20241201 article-title: SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. publication-title: Hepatology doi: 10.1002/hep.22859 – volume: 46 start-page: 395 year: 2007 ident: R21-9-20241201 article-title: Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. publication-title: J Hepatol doi: 10.1016/j.jhep.2006.09.020 – volume: 21 start-page: 28 year: 2009 ident: R10-9-20241201 article-title: Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C. publication-title: Eur J Gastroenterol Hepatol doi: 10.1097/MEG.0b013e32830cebd7 – volume: 32 start-page: 1050 year: 2008 ident: R12-9-20241201 article-title: Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests. publication-title: Gastroenterol Clin Biol doi: 10.1016/j.gcb.2008.09.017 – volume: 50 start-page: 1061A issue: Suppl 4 year: 2009 ident: R15-9-20241201 article-title: Independent and prospective comparison of 9 surrogate markers for the diagnosis of liver fibrosis in chronic hepatitis C Abstract. publication-title: Hepatology – volume: 128 start-page: 343 year: 2005 ident: R1-9-20241201 article-title: Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. publication-title: Gastroenterology doi: 10.1053/j.gastro.2004.11.018 – volume: 28 start-page: 1352 year: 2008 ident: R13-9-20241201 article-title: Evaluating accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C. publication-title: Liver Int doi: 10.1111/j.1478-3231.2008.01789.x – volume: 41 start-page: 1368 year: 2008 ident: R16-9-20241201 article-title: Diagnostic accuracy, reproducibility and robustness of fibrosis blood tests in chronic hepatitis C: a meta-analysis with individual data. publication-title: Clin Biochem doi: 10.1016/j.clinbiochem.2008.06.020 – volume: 49 start-page: 1083 year: 2009 ident: R20-9-20241201 article-title: Factors of accuracy of transient elastography (Fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C. publication-title: Hepatology doi: 10.1002/hep.22748 – volume: 29 start-page: 1507 year: 2009 ident: R8-9-20241201 article-title: The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis. publication-title: Liver Int doi: 10.1111/j.1478-3231.2009.02101.x – volume: 48 start-page: 418 year: 2008 ident: R22-9-20241201 article-title: Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. publication-title: Hepatology doi: 10.1002/hep.22375 – volume: 106 start-page: 1255 year: 2011 ident: R14-9-20241201 article-title: A new combination of blood test and Fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C. publication-title: Am J Gastroenterol doi: 10.1038/ajg.2011.100 – volume: 50 start-page: 36 year: 2009 ident: R24-9-20241201 article-title: Exceeding the limits of liver histology markers. publication-title: J Hepatol doi: 10.1016/j.jhep.2008.07.039 – volume: 41 start-page: 10 year: 2008 ident: R18-9-20241201 article-title: Reproducibility of blood tests of liver fibrosis in clinical practice. publication-title: Clin Biochem doi: 10.1016/j.clinbiochem.2007.08.009 – volume: 44 start-page: 686 year: 2006 ident: R2-9-20241201 article-title: Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. publication-title: J Hepatol doi: 10.1016/j.jhep.2006.01.007 – volume: 28 start-page: 458 year: 2008 ident: R4-9-20241201 article-title: Optimized stepwise combination algorithms of non-invasive liver fibrosis scores including Hepascore in hepatitis C virus patients. publication-title: Aliment Pharmacol Ther doi: 10.1111/j.1365-2036.2008.03742.x – volume: 7 start-page: 696 year: 2009 ident: R5-9-20241201 article-title: Validation of Hepascore, compared to simple indices of fibrosis, in US patients with chronic hepatitis C virus infection. publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2009.01.010 – volume: 52 start-page: 191 year: 2010 ident: R7-9-20241201 article-title: Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. publication-title: J Hepatol doi: 10.1016/j.jhep.2009.11.008 – volume: 38 start-page: 518 year: 2003 ident: R17-9-20241201 article-title: A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. publication-title: Hepatology doi: 10.1053/jhep.2003.50346 – volume: 13 start-page: 659 year: 2006 ident: R3-9-20241201 article-title: Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies. publication-title: J Viral Hepat doi: 10.1111/j.1365-2893.2006.00736.x – volume: 48 start-page: 835 year: 2008 ident: R19-9-20241201 article-title: Non-invasive evaluation of liver fibrosis using transient elastography. publication-title: J Hepatol doi: 10.1016/j.jhep.2008.02.008 – volume: 51 start-page: 354 year: 2010 ident: R9-9-20241201 article-title: Limitations of the algorithm for the SAFE biopsy: a noninvasive fibrosis measure in chronic hepatitis C. publication-title: Hepatology doi: 10.1002/hep.23185 – volume: 50 start-page: 656 year: 2009 ident: R11-9-20241201 article-title: Combination of fibrosis tests: sequential or synchronous? publication-title: Hepatology doi: 10.1002/hep.23069 – volume: 50 start-page: 1 year: 2009 ident: R23-9-20241201 article-title: Liver biopsy: the best, not the gold standard. publication-title: J Hepatol doi: 10.1016/j.jhep.2008.10.014 – reference: 22162013 - Hepatology. 2012 Feb;55(2):652-3; author reply 653 |
| SSID | ssj0009428 |
| Score | 2.3995638 |
| Snippet | The sequential algorithm for fibrosis evaluation (SAFE) and the Bordeaux algorithm (BA), which cross‐check FibroTest with the aspartate... The sequential algorithm for fibrosis evaluation (SAFE) and the Bordeaux algorithm (BA), which cross-check FibroTest with the aspartate... UNLABELLED: The sequential algorithm for fibrosis evaluation (SAFE) and the Bordeaux algorithm (BA), which cross-check FibroTest with the aspartate... |
| SourceID | hal proquest pubmed pascalfrancis crossref wiley istex |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 58 |
| SubjectTerms | Accuracy Adult Algorithms Biological and medical sciences Biological Markers Biomarkers - blood Biopsy Classification Decision Trees Diagnostic Techniques, Digestive System Diagnostic Techniques, Digestive System - standards Elasticity Imaging Techniques Female Gastroenterology Gastroenterology - methods Gastroenterology - standards Gastroenterology. Liver. Pancreas. Abdomen Hepatitis Hepatitis C Hepatitis C virus Hepatitis C, Chronic Hepatitis C, Chronic - classification Hepatitis C, Chronic - diagnosis Hepatology Human health and pathology Human viral diseases Humans Hépatology and Gastroenterology Infectious diseases Life Sciences Liver Liver Cirrhosis Liver Cirrhosis - classification Liver Cirrhosis - diagnosis Liver. Biliary tract. Portal circulation. Exocrine pancreas Male Medical sciences Middle Aged Other diseases. Semiology Reproducibility of Results Sensitivity and Specificity Viral diseases Viral hepatitis |
| Title | Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive |
| URI | https://api.istex.fr/ark:/67375/WNG-33H4V04Q-J/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhep.24654 https://www.ncbi.nlm.nih.gov/pubmed/21898504 https://www.proquest.com/docview/1766825352 https://www.proquest.com/docview/1776668529 https://www.proquest.com/docview/912639475 https://hal.science/hal-00866967 |
| Volume | 55 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1527-3350 dateEnd: 20241102 omitProxy: true ssIdentifier: ssj0009428 issn: 0270-9139 databaseCode: DIK dateStart: 19960101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVWIB databaseName: Wiley Online Library - Core collection (SURFmarket) issn: 0270-9139 databaseCode: DR2 dateStart: 19960101 customDbUrl: isFulltext: true eissn: 1527-3350 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0009428 providerName: Wiley-Blackwell |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfGkBAvfDMCYzIIob2kSxw7juFpqjaqiU2AGOwByXIch1YrbdW0E_DO_82d81GKNgnxlo9zHDvn8-_sy-8IeZHbDAyjK8M8lWXIrRKhKYwMbeE4szBDCp-m8_gkHZzyozNxtkFet__C1PwQ3YIbjgxvr3GAm7zaW5GGDt2sx5ANDOxvnKTenfqwoo5S3OdVBa8rwt1l1bIKRWyvK7k2F10bYiTkdezc7xghaSropLLObnEZ_FxHs346OrxNvrQNqaNQznvLRd6zP__iePzPlt4htxqYSvdrvbpLNtzkHrlx3GzE3ye_-l3-QjotqV9fpUUdtgdFqBl_nc5Hi-G3igIqpmOM_qAlvMW0GlV0NKFQGyoqnPRfUYD2f5Ywc0cx_pfOkHqjctRMCopRTXM3_kEnuIB8YTDs_gE5PTz42B-ETUaH0IJjxEPFrMyMzXH3skwYGgPrlDU8tVwWJrPGZQYwJYDASNpEYmp2IWNnXFGIIo6Th2QTanGPCE1Bk6RVGXMi505EJjaANQoFeMRkUrGA7LbfVtuG7hyzbox1TdTMNDRU-24NyPNOdFZzfFwqBArS3UdW7sH-W43X0C1MVSov4oC89PrTiZn5OUbOSaE_n7zRSTLgnyL-Xh8FZGdNwboC4OEBpFMqINutxunGqlQayTzBowfMHJBn3W2wB7jJYyZuukQZEEozweAR9AoZFTMAplyKgGzVyryqP85UJiJo7q5Xyas7RA8O3vmDx_8u-oTcBMDJ6iWsbbK5mC_dUwB1i3zHj97f25FG2w |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELf2IcFe-P4IjGEQQntJl7h2HCNepmojjLYCtI29IMtxnLVaaaumnYB3_m_ukjalaJMQb01zrmP3fP7d-fI7Ql6lNgbD6HI_jWTuc6uEbzIjfZs5zizskKIs09npRskJPzoTZ2vk7eJdmIofog644coo7TUucAxI7y1ZQ3tu3GBIB7ZONnkEfgpCos9L8ijFy8qq4HcFeL6sFrxCAdurm67sRus9zIXcxOn9jjmSpoBpyqv6FlcB0FU8W25Ih7fJ18VQqjyUi8Zsmjbsz79YHv93rHfIrTlSpfuVat0la254j9zozM_i75NfrbqEIR3ltAyx0qzK3IMm1AzOR5P-tPetoACM6QATQGgOjzEq-gXtDyn0hroKF603FND9ny3MxFFMAaZjZN8oHDXDjGJi08QNftAhxpAvDWbePyAnhwfHrcSfF3XwLfhG3FfMytjYFA8w8yZDe2CdsoZHlsvMxNa42ACsBBwYSNuUWJ1dyNAZl2UiC8PmQ7IBvbjHhEagTNKqmDmRcicCExqAG5kCSGJiqZhHdhd_rrZzxnMsvDHQFVcz0zBQXU6rR17WouOK5uNKIdCQ-j4Scyf7bY3foWcYqUhehh55XSpQLWYmF5g8J4X-0n2nm82Enwb8kz7yyM6KhtUNwMkDVKeUR7YXKqfnhqXQyOcJTj3AZo-8qG-DScBzHjN0oxnKgFAUCwY_Qa-RUSEDbMql8MijSpuX_YexikUAw90tdfL6CdHJwcfyw5N_F31ObibHnbZuv-9-eEq2AH-yKqK1TTamk5l7Bhhvmu6US_k3NjRK_A |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFD7aRZp44X4JjGEQQntJl7hOHCNepm6ljG0aiI29IMtxHFqttFXTTsA7_5tzkjalaJMQb01zXMfusf0d-8t3AF6mNsGJ0eV-GsvcF1ZFvsmM9G3mBLe4QkZlms6j47hzKg7Oo_MVeDN_F6bSh6g33GhklPM1DXA3yvKdhWpo140anOTAVmFdRCohQt_ex4V4lBJlZlWMuwI6X1ZzXaGA79RFl1aj1S5xIdepe78TR9IU2E15ld_iKgC6jGfLBal9C77Mm1LxUC4a00nasD__Unn837behpszpMp2K9e6AytucBc2jmZn8ffgV6tOYciGOSu3WFlWMfewCDP9r8Nxb9L9VjAExqxPBBCW42MMi17BegOGtZGv4kXrNUN0_2cJM3aMKMBsROobhWNmkDEiNo1d_wcb0B7ypSHm_X04be9_anX8WVIH32JsJHzFrUyMTekAM29ymg-sU9aI2AqZmcQalxiElYgDA2mbkrKzRzJ0xmVZlIVh8wGsYS3uEbAYnUlalXAXpcJFgQkNwo1MISQxiVTcg-35n6vtTPGcEm_0daXVzDU2VJfd6sGL2nRUyXxcaYQeUt8nYe7O7qGm7ygyjFUsL0MPXpUOVJuZ8QWR52SkPx-_1c1mR5wF4oM-8GBrycPqAhjkIapTyoPNucvp2cRSaNLzxKAeYbMHz-vbOCXQOY8ZuOGUbNAoTiKOP8GusVEhR2wqZOTBw8qbF_WHCQ6mAJu7Xfrk9R2iO_sn5YfH_276DDZO9tr68N3x-ydwA-Enrza0NmFtMp66pwjxJulWOZJ_A3lmSoA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparison+of+Eight+Diagnostic+Algorithms+for+Liver+Fibrosis+in+Hepatitis+C%3A+New+Algorithms+Are+More+Precise+and+Entirely+Noninvasive&rft.jtitle=Hepatology+%28Baltimore%2C+Md.%29&rft.au=BOURSIER%2C+J%C3%A9r%C3%B4me&rft.au=DE+LEDINGHEN%2C+Victor&rft.au=ZARSKI%2C+Jean-Pierre&rft.au=FOUCHARD-HUBERT%2C+Isabelle&rft.date=2012&rft.pub=Wiley&rft.issn=0270-9139&rft.volume=55&rft.issue=1&rft.spage=58&rft.epage=67&rft_id=info:doi/10.1002%2Fhep.24654&rft.externalDBID=n%2Fa&rft.externalDocID=25543199 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0270-9139&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0270-9139&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0270-9139&client=summon |